Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia
Publication
, Journal Article
Doucette, K; Percival, M; Williams, L; Kandahari, A; Taylor, A; Wang, S; Ahn, J; Karp, JE; Lai, C
Published in: Hematological Oncology
Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment‐related complications, as well as short‐term mortality and overall survival (OS) in 756 newly diagnosed AML patients. We conducted a retrospective multicenter study to examine treatment‐related complications and OS according to pretreatment serum albumin levels: normal albumin ≥3.5 g/dl, marked hypoalbuminemia <2.5 g/dl, and hypoalbuminemia 2.5–3.4 g/dl. In an adjusted multivariate analysis, a lower baseline albumin was independently associated with a higher number of grade ≥3 complications when adjusting for age, secondary AML, sex and intensive treatment. When comparing normal to markedly low albumin levels, the estimated mean number of complications increases by a factor of 1.35. Patients who had a normal baseline albumin had a 30 day‐mortality rate of 4.8%, which was significantly lower compared with patients with hypoalbuminemia (16.5%) and marked hypoalbuminemia (33.9%; < 0.01). Similarly, 60‐day mortality rate was significantly higher in the hypoalbuminemia group (24.0%) and marked hypoalbuminemia group (45%) compared with normal albumin group (8.3%; < 0.01). Patients with lower baseline albumin levels have increased treatment‐related morbidity and mortality, suggesting that pre‐treatment serum albumin is an important independent prognostic marker.
Altmetric Attention Stats
Dimensions Citation Stats